Patients with specific subtypes, namely hormone receptor (HR)−/human epidermal growth factor receptor 2 (HER2)+ and triple-negative breast cancer (TNBC), can achieve pCR rates of up to 68%3–5. Here, NR4A1 is linked to triple-negative breast carcinoma.